Ectopic Pregnancy
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
Separate haemodynamic emergencies from stable tubal ectopic pregnancy. Outpatient treatment depends on both clinical eligibility and reliable access to repeat assessment.
Assessment & interpretation
- Assess pain, bleeding, circulation, scan size, fetal cardiac activity and quantitative hCG. Confirm that a viable intrauterine pregnancy has been excluded before methotrexate.
- Check whether the patient can return for monitoring and understands the possibility of urgent admission.
Decisions that change management
- NICE offers expectant care for a pain-free, stable patient with a tubal mass below 35 mm, no heartbeat and hCG at most 1,000 IU/L; consider it when hCG is above 1,000 but below 1,500.
- Surgery is first line for significant pain, a mass at least 35 mm, visible fetal heartbeat, hCG at least 5,000 IU/L, or inability to attend follow-up.
Follow-up & safety-netting
- After methotrexate, check hCG on days 4 and 7, then weekly until negative. Plateauing or rising values require reassessment.
- After salpingotomy, measure hCG at day 7 and weekly thereafter. After salpingectomy, arrange a urine pregnancy test at 3 weeks and review a positive result.
Clinical pitfalls
- Falling hCG does not replace clinical assessment when new pain or collapse develops.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Suspected rupture, instability, significant pain or major bleeding requires admission and urgent surgery. Inability to return for follow-up or surgical-treatment criteria changes the management choice.
When clinic, day care or home care may be suitable
- Expectant or methotrexate treatment requires documented eligibility, no significant pain/instability and reliable access to serial hCG and emergency care.
Before going home
- After surgery: observations, bleeding, pain, oral intake, mobilisation and voiding are satisfactory, with review of operative findings/complications.
- After medical/expectant selection: treatment and follow-up eligibility are confirmed, hCG appointments are booked and emergency access is feasible. Discharge does not mean that rupture risk has ended.
Discharge medicines and treatment changes
- If methotrexate was administered, give the checked regimen-specific interaction, breastfeeding and contraception advice. No automatic repeat dose is a discharge instruction.
- After surgery provide the indicated oral analgesic and review any VTE/anti-D requirements.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
For uncomplicated postoperative pain when prescribed; increasing pain still needs assessment.
- Indication: Short-term maternal postoperative/postpartum pain or other mild pain after assessment; adult ≥50 kg
- MSF oral monograph: no pregnancy or breastfeeding contraindication. The dose does not replace assessment of the cause of pain.
- Pain and functional recovery; investigate increasing pain, fever or other warning symptoms.
- Check all prescribed/OTC paracetamol, weight and hepatic risk; suspected excess dosing requires urgent assessment.
Tests, pending results and their reviewer
- Methotrexate: hCG on days 4 and 7, then weekly until negative, with review of inadequate fall/plateau/rise.
- Expectant management: hCG days 2, 4 and 7, then weekly if the expected fall occurs. After salpingotomy: hCG at day 7 then weekly; after salpingectomy: urine pregnancy test at 3 weeks, review if positive.
Home care and counselling
- Give written rupture symptoms, avoid becoming pregnant until the methotrexate follow-up/contraception interval is completed, and arrange an early assessment in the next pregnancy.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
Before leaving | Book the exact hCG/urine-test schedule for the treatment received; identify the results reviewer. |
At treatment completion | Review recovery, fertility implications, contraception and early scanning in a future pregnancy. |
Return urgently
- Increasing abdominal/shoulder-tip pain, faintness, collapse, heavy bleeding, breathlessness or fever requires immediate assessment.
Treatment
① Immediate stabilization — first minutes
② Assessment & investigations
- Never delay unstable patients for imaging beyond bedside US
③ First-line treatment & drug regimens
- Selected stable unruptured tubal ectopic pregnancy with assured follow-up; NICE selection criteria apply
- The NHS GGC protocol had a scheduled review date in September 2026; its local currency must be confirmed. NICE is used for eligibility.
- If the day-4-to-day-7 fall is inadequate, do not automatically redose: reassess symptoms, hCG trend, eligibility and the need for surgery with a senior clinician.
- Baseline CBC, liver/renal function and hCG; day-4/day-7 hCG, then weekly
- Seek emergency care for worsening abdominal/shoulder-tip pain, dizziness, syncope or heavy bleeding
- Avoid folate supplements, interacting NSAIDs and alcohol as advised; avoid conception for 3 months
- Multidose MTX protocol (1 mg/kg alternating leucovorin) — specialist centres for heartbeat/hCG>5000 cases
- Expectant management per table above
Definitive treatment
- SURGERY (laparoscopic preferred):
- Salpingectomy when contralateral tube healthy — lower persistent-trophoblast risk
- Consider salpingotomy when other infertility risks exist; plan hCG at day 7 and weekly thereafter to negative
- Interstitial/angular pregnancies: specialist-led (cornual resection/hysterectomy risk counselling; MTX/systemic±local injection options)
- Caesarean-scar ectopic: expert-centre options (HIFU/D&C under US±balloon, laparoscopic excision, UAE adjuncts)
- Cervical: UAE + medical/surgical per centre expertise
Monitoring
| Pathway | Schedule |
|---|---|
Post-MTX | hCG d4, d7, then weekly to negative; CBC/LFT day 7 |
Post-salpingostomy | Serum hCG at day 7 after surgery, then weekly to negative |
RhD prophylaxis decision | Use gestation-specific NICE NG126 (June 2026) criteria; confirm applicability of the local policy |
Response assessment
- hCG declining ≥15% d4→d7 (MTX)
- Post-op hCG trending down appropriately
Treatment failure
- MTX failure signs: rising/plateaued hCG, new/worsening pain, free fluid growth → SURGERY (do not simply re-dose beyond protocol)
- Persistent trophoblast post-salpingostomy: MTX 50 mg/m² rescue
Procedure / surgery
Laparoscopy is standard-of-care approach (faster recovery, less blood loss); laparotomy for instability/massive haemoperitoneum per surgeon judgement.
Escalation
- Massive haemoperitoneum → MTP + senior surgeon + anaesthetist simultaneously
- Rare cervical/caesarean-scar haemorrhage: UAE standby
⑮ Complications & their management
Haemorrhagic shock
Per massive-transfusion protocol; warm products; calcium; consider cell salvage
Persistent ectopic post-surgery/MTX
Weekly-hCG surveillance catches it; treat as above
Recurrent ectopic (~10%)
Early scan next pregnancy at 5–6 wks; fertility counselling (hSG assessment of remaining tube)
Post-treatment care
- hCG confirmation of resolution
- Anti-D where indicated
- Psychological support (pregnancy loss + emergency)
- STI screening offer (PID association); partner treatment
- Preconception planning: early-scan policy next pregnancy
Classification
| Option | Typical criteria | Key numbers |
|---|---|---|
Expectant | Stable and pain-free, tubal mass <35 mm, no heartbeat; offer if hCG ≤1000 IU/L, consider if >1000 and <1500 | Repeat hCG on days 2, 4 and 7, then weekly if falling appropriately |
Methotrexate (single-dose protocol) | No significant pain; unruptured tubal mass <35 mm, no heartbeat; viable IUP excluded; reliable follow-up; baseline safety bloods acceptable | NICE: offer MTX if hCG <1500; offer MTX or surgery at 1500–<5000 when eligible; reassess response on days 4 and 7 |
Salpingectomy (laparoscopic) | Contralateral tube healthy; rupture/unstable; MTX failure; large/heart-beat masses | Gold standard surgical treatment |
Salpingostomy | Only tube affected / desire future fertility (specialist decision) | Higher persistent-trophoblast rate (~14–20%) — weekly hCG mandatory |
Diagnosis & assessment
- HAEMODYNAMIC INSTABILITY — straight to theatre
- Shoulder-tip pain/rebound guarding
- Cervical motion tenderness with fainting
- βhCG rising + empty uterus + any pain
Definition: Pregnancy implanted outside the uterine cavity — fallopian tube (ampullary commonest), interstitial, ovarian, caesarean-scar, cervical, abdominal.
Risk factors
Presentation
- Amenorrhoea 6–8 wks + unilateral pelvic pain + PV bleeding (classic triad incomplete)
- Diarrhoea/vomiting (pelvic irritation) misleads
- Shoulder-tip pain/dizziness (haemoperitoneum)
- Up to 50% asymptomatic before rupture on first scans
Initial assessment
- ABC + vitals; two IV lines if unstable
- Urine/serum hCG FIRST in every reproductive-age woman with abdominal pain
- TVS: empty uterus? adnexal mass? free fluid? pseudosac caution
- Bloods: CBC, group&save/crossmatch, hCG quantitative, Rh
- Stable → pathway selection below; UNSTABLE → resuscitate + emergency laparotomy/laparoscopy
Investigations
| Test | Looking for |
|---|---|
TVS | Adnexal sac ± yolk sac/fetal pole; interstitial line sign; "bagel sign" |
Quantitative βhCG serial | Kinetics guiding eligibility for MTX vs expectant vs surgery |
CBC + coags if bleeding | Anaemia/coagulopathy before surgery |
Differential diagnosis
| Condition | Clue |
|---|---|
Corpus luteum bleed | Similar pain; ring of fire on Doppler but no gestational sac |
Threatened/incomplete miscarriage | Central cramping, visible IUP |
Torted adnexa | Vomiting prominent; ovular mass |
Appendicitis | Migrating pain, fever, GI focus |
Algorithm
Principles & follow-up
Management principles
Special situations
Guideline conflict
NICE NG126 — national selection criteria
Surgery is first line for a tubal mass ≥35 mm, visible fetal heartbeat, hCG ≥5000 IU/L, significant pain or inability to attend follow-up.
NHS GGC local methotrexate protocol — dose reference
The local protocol uses a ≥4 cm mass exclusion threshold and requires consultant review; its eligibility criteria are not identical to NICE.
Population/setting difference: Both concern stable ectopic pregnancy, but one is national guidance and the other a local hospital protocol.
Practical India consideration: Check the current institutional ectopic pathway; do not import a UK local eligibility threshold without review.
Reason: Separates patient selection from the dose reference and makes the differing thresholds explicit.
Sources (9)
17 April 2019 · updated 17 June 2026 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for ectopic-pregnancy. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Also corrected stable-tubal-e…
· checked 2026-10-17 · verified-summary
Open source ↗
Checked the 50 mg/m² IM initial dose, day-4/day-7 hCG assessment, ≥15% fall criterion and senior reassessment before further doses. The document records a next review date of 30 September 2026, already past at this check; current local protocol should be confirmed. NICE national criteria are used fo…
2019-04-17 · updated 2026-06-17 · checked 2026-10-18 · verified-live
Open source ↗
Recommendations 1.18.1–1.18.5: no routine anti-D up to 11+6 weeks; offer to RhD-negative patients having medical or surgical management at 12+0–12+6 weeks, consider for heavy/recurrent threatened bleeding at that gestation. Corrected blanket all-loss anti-D wording; applicability to local Indian pol…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary oral monograph read: adult 1 g 3–4 times daily, maximum 4 g/day, ≥50 kg adult table, 500 mg tablets, duration according to response, hepatic caution and pregnancy/breastfeeding. Pain chapter also checked for 6–8-hour interval. Smaller adults require an individual weight-based prescripti…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.